StockData
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc. (VRCA) stock

VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$3.14−0.06 (-1.88%)

Close on Nov 17, 2026Market cap $53.94MP/E –Yield –

Earnings

Verrica Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 10, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$6.90M
-51.7% on a year earlier
non-GAAP net loss, Q3 FY2026
-$0.49
$0.13 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Verrica Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Mar 10, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 12, 2026after the close$6.90M-51.7%-$0.58-$0.49Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026during market hours$5.90M-53.5%-$0.62-$0.48Release
Q1 FY2026ended Mar 31, 2026May 12, 2026during market hours$5.00M–-$0.45-$0.41Release
Q4 FY2025ended Dec 31, 2025Mar 11, 2026before the open$5.09M–-$0.57-$0.51Release
Q3 FY2025ended Sep 30, 2025Nov 14, 2025during market hours$14.30M–-$0.03$0.13Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025during market hours$12.70M+145.3%$0.02$0.25Release
Q1 FY2025ended Mar 31, 2025May 13, 2025during market hours–––-$0.08Release
Q4 FY2024ended Dec 31, 2024Mar 11, 2025during market hours––––Release
Q3 FY2024ended Sep 30, 2024Nov 4, 2024during market hours-$1.78M-161.1%-$0.49-$0.43Release
Q2 FY2024ended Jun 30, 2024Aug 14, 2024before the open$5.18M+2488.5%-$0.37-$0.31Release
Q1 FY2024ended Mar 31, 2024May 13, 2024before the open$3.83M+10240.5%-$0.44-$0.38Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Verrica Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Verrica Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Verrica Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. News
  6. Results
  7. Results
  8. Update
  9. Results
  10. Results
  11. News
  12. News
  13. News
  14. Results
  15. Results

See a number that looks wrong?